News

Dr. Dolly Jacob, Director of Integrated Development Services at Quotient Sciences featured in Drug Development & Delivery looking at the challenges of solubility & bioavailability.

Dr. Vanessa Zann, Senior Drug Development Consultant at Quotient Sciences featured in Pharmaceutical Technology looking at the important role of early-phase biopharmaceutics.

Quotient Sciences experts contribute to a recent article in the American College of Clinical Pharmacology® Clinical Pharmacology in Drug Development journal that highlights the results of an ADME study of AstraZeneca's savolitinib.

An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.

Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.

HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.